Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
Regenxbio Inc (NASDAQ: RGNX) closed the day trading at $8.85 down -1.34% from the previous closing price of $8.97. In other words, the price has decreased by -$1.34 from its previous closing price. On the day, 0.83 million shares were traded.
Ratios:
For a better understanding of RGNX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.93 and its Current Ratio is at 2.93. In the meantime, Its Debt-to-Equity ratio is 0.49 whereas as Long-Term Debt/Eq ratio is at 0.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 11, 2025, Downgraded its rating to Neutral and sets its target price to $14 from $38 previously.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 12 ’25 when Mills Kenneth T. sold 20,602 shares for $7.91 per share. The transaction valued at 163,046 led to the insider holds 475,103 shares of the business.
KENNETH MILLS bought 20,602 shares of RGNX for $154,927 on May 12 ’25. On Dec 30 ’24, another insider, VITTAL VASISTA, who serves as the Officer of the company, bought 20,041 shares for $7.41 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.83 while its Price-to-Book (P/B) ratio in mrq is 1.62.
Stock Price History:
Over the past 52 weeks, RGNX has reached a high of $15.36, while it has fallen to a 52-week low of $5.03. The 50-Day Moving Average of the stock is 10.37%, while the 200-Day Moving Average is calculated to be -0.95%.
Shares Statistics:
A total of 50.12M shares are outstanding, with a floating share count of 45.52M. Insiders hold about 9.25% of the company’s shares, while institutions hold 87.57% stake in the company.
Earnings Estimates
Regenxbio Inc (RGNX) is currently under the scrutiny of 6.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $1.08, with high estimates of $2.6 and low estimates of -$1.18.
Analysts are recommending an EPS of between $2.7 and -$3.36 for the fiscal current year, implying an average EPS of $0.23. EPS for the following year is -$1.52, with 7.0 analysts recommending between $0.99 and -$4.4.
Revenue Estimates
9 analysts predict $40.87M in revenue for the current quarter. It ranges from a high estimate of $142.89M to a low estimate of $20M. As of the current estimate, Regenxbio Inc’s year-ago sales were $22.3MFor the next quarter, 9 analysts are estimating revenue of $110.02M. There is a high estimate of $222M for the next quarter, whereas the lowest estimate is $21M.
A total of 11 analysts have provided revenue estimates for RGNX’s current fiscal year. The highest revenue estimate was $425.21M, while the lowest revenue estimate was $150M, resulting in an average revenue estimate of $335.87M. In the same quarter a year ago, actual revenue was $83.33MBased on 11 analysts’ estimates, the company’s revenue will be $283.87M in the next fiscal year. The high estimate is $482.9M and the low estimate is $91.84M.
